Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Ticagrelor monotherapy beats DAPT in STEMI

Key clinical point: STEMI patients who dropped aspirin from DAPT after 3 months and continued ticagrelor as monotherapy fared better at 1 year than with a full year of DAPT.

Major finding: The 1-year net adverse clinical event rate in an as-treated analysis was 5.2% with 12 months of DAPT and 2.3% with ticagrelor monotherapy.

Study details: This was a prospective, randomized, open-label trial of 1,103 STEMI patients followed for 1 year post PCI.

Disclosures: The presenter reported having no financial conflicts regarding the trial, funded by Biotronik.


AT TCT 2020